Weekly roundup: From BIO 2025 to building boards
Rewind Therapeutics strengthens scientific advisory board with leading international neurology experts as it advances its first-in-class remyelination therapy Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has appointed four internationally recognised innovators in neurology – Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan – to its Scientific Advisory Board (SAB). The […]